Literature DB >> 10456459

Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule.

M E Bromberg1, R Sundaram, R J Homer, A Garen, W H Konigsberg.   

Abstract

Tissue factor (TF) is a transmembrane glycoprotein that complexes with factor VIIa to initiate blood coagulation. It was reported in an earlier study that expression of high levels of TF in a human melanoma cell line promotes metastasis, and that the cytoplasmic domain of TF is required for this metastatic effect. To analyze the functions of the cytoplasmic and extracellular domains of TF in metastasis, two TF mutants were constructed; in one mutant alanine was substituted for each of the three serine residues in the cytoplasmic domain, preventing phosphorylation; in the other mutant alanine was substituted for four key residues in the extracellular domain, preventing binding of factor VIIa and consequently eliminating the initiation of blood coagulation by the TF-VIIa complex. Melanoma lines expressing high levels of either mutant form of TF were weakly metastatic in SCID mice, indicating that phosphorylation of the cytoplasmic domain and formation of a complex with VIIa by the extracellular domain are required for the full metastatic effect of TF. It was also found that increasing TF expression in human melanoma cells does not increase expression of vascular endothelial growth factor or promote growth and vascularization of tumors derived from the melanoma cells, suggesting that TF acts by a mechanism other than angiogenesis to promote metastasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456459

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  21 in total

Review 1.  Tissue factor and PAR2 signaling in the tumor microenvironment.

Authors:  Florence Schaffner; Wolfram Ruf
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-06       Impact factor: 8.311

2.  Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms.

Authors:  Joseph S Palumbo; Kathryn E Talmage; Jessica V Massari; Christine M La Jeunesse; Matthew J Flick; Keith W Kombrinck; Zhiwei Hu; Kelley A Barney; Jay L Degen
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

Review 3.  Treatment of cancer with anticoagulants: rationale in the treatment of melanoma.

Authors:  D L Ornstein; L R Zacharski
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

4.  Preoperative D-dimers as an independent prognostic marker in cervical carcinoma.

Authors:  Yao-Ling Luo; Pei-Dong Chi; Xin Zheng; Lin Zhang; Xue-Ping Wang; Hao Chen
Journal:  Tumour Biol       Date:  2015-06-14

Review 5.  Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.

Authors:  Nicole M Kuderer; Thomas L Ortel; Charles W Francis
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

6.  Cross-talk of integrin alpha3beta1 and tissue factor in cell migration.

Authors:  Andrea Dorfleutner; Edith Hintermann; Takehiko Tarui; Yoshikazu Takada; Wolfram Ruf
Journal:  Mol Biol Cell       Date:  2004-07-14       Impact factor: 4.138

7.  Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration.

Authors:  Gertrud M Hjortoe; Lars C Petersen; Tatjana Albrektsen; Brit B Sorensen; Peder L Norby; Samir K Mandal; Usha R Pendurthi; L Vijaya Mohan Rao
Journal:  Blood       Date:  2004-01-08       Impact factor: 22.113

8.  Tissue factor mediates the HGF/Met-induced anti-apoptotic pathway in DAOY medulloblastoma cells.

Authors:  Mathieu Provençal; Nancy Berger-Thibault; David Labbé; Ryan Veitch; Dominique Boivin; Georges-Etienne Rivard; Denis Gingras; Richard Béliveau
Journal:  J Neurooncol       Date:  2009-11-18       Impact factor: 4.130

9.  Tissue factor as a novel target for treatment of breast cancer.

Authors:  Marion Cole; Michael Bromberg
Journal:  Oncologist       Date:  2013-01-03

10.  Development of 131I-ixolaris as a theranostic agent: metastatic melanoma preclinical studies.

Authors:  Thiago Barboza; Tainá Gomes; Priscylla da Costa Medeiros; Isalira Peroba Ramos; Ivo Francischetti; Robson Q Monteiro; Bianca Gutfilen; Sergio Augusto Lopes de Souza
Journal:  Clin Exp Metastasis       Date:  2020-05-11       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.